Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMUS 004 biomarker-directed second-line treatments in metastatic pancreatic cancer
2018-003971-37Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ceralasertib and olaparib in pancreatic cancer (PC) and pancreatic cancer (PDAC) (3 cohorts), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Objective response rate. Status: unknown.
02
Drugs
ceralasertibolaparib
03
Conditions
pancreatic cancer (PC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2018-003971-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003971-37.